ClearPoint Neuro, Inc. (CLPT) stock
CLPTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3021% above fair value
$8.48−0.01 (-0.12%)
Close on Nov 13, 2026Market cap $271.82MP/E –Yield –
ClearPoint Neuro r&d expenses
Research and development expenses are spending on new products and technology.
ClearPoint Neuro's R&D Expenses for the twelve months ending Sep 30, 2026 was $16.41M, up 17.3% year over year. For fiscal 2025 it was $13.90M, up 12.1% from the year before. Over ten years it grew 21.7% a year on average. The highest annual figure on record is $13.90M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.90M | +12.1% |
| FY2024 | Dec 31, 2024 | $12.39M | +5.8% |
| FY2023 | Dec 31, 2023 | $11.71M | +7.5% |
| FY2022 | Dec 31, 2022 | $10.89M | +17.4% |
| FY2021 | Dec 31, 2021 | $9.28M | +98.1% |
| FY2020 | Dec 31, 2020 | $4.69M | +66.8% |
| FY2019 | Dec 31, 2019 | $2.81M | +21.6% |
| FY2018 | Dec 31, 2018 | $2.31M | -17.9% |
| FY2017 | Dec 31, 2017 | $2.81M | +7.1% |
| FY2016 | Dec 31, 2016 | $2.63M | +34.3% |
| FY2015 | Dec 31, 2015 | $1.96M | -40.6% |
| FY2014 | Dec 31, 2014 | $3.30M | +12.8% |
| FY2013 | Dec 31, 2013 | $2.92M | +17.6% |
| FY2012 | Dec 31, 2012 | $2.48M | -41.6% |
| FY2011 | Dec 31, 2011 | $4.25M | -25.2% |
| FY2010 | Dec 31, 2010 | $5.68M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.02M | +16.4% |
| Q2 FY2026 | Jun 30, 2026 | $4.63M | +21.0% |
| Q1 FY2026 | Mar 31, 2026 | $4.52M | +33.8% |
| Q4 FY2025 | Dec 31, 2025 | $3.24M | -2.9% |
| Q3 FY2025 | Sep 30, 2025 | $3.45M | +4.1% |
| Q2 FY2025 | Jun 30, 2025 | $3.83M | +22.7% |
| Q1 FY2025 | Mar 31, 2025 | $3.38M | +28.7% |
| Q4 FY2024 | Dec 31, 2024 | $3.33M | +25.6% |
| Q3 FY2024 | Sep 30, 2024 | $3.32M | +36.5% |
| Q2 FY2024 | Jun 30, 2024 | $3.12M | -13.5% |
| Q1 FY2024 | Mar 31, 2024 | $2.63M | -13.2% |
| Q4 FY2023 | Dec 31, 2023 | $2.65M | -9.4% |
| Q3 FY2023 | Sep 30, 2023 | $2.43M | -8.5% |
| Q2 FY2023 | Jun 30, 2023 | $3.61M | +49.5% |
| Q1 FY2023 | Mar 31, 2023 | $3.02M | +4.2% |
| Q4 FY2022 | Dec 31, 2022 | $2.93M | -4.8% |
| Q3 FY2022 | Sep 30, 2022 | $2.65M | +2.0% |
| Q2 FY2022 | Jun 30, 2022 | $2.41M | +14.3% |
| Q1 FY2022 | Mar 31, 2022 | $2.90M | +85.6% |
| Q4 FY2021 | Dec 31, 2021 | $3.07M | +60.7% |
| Q3 FY2021 | Sep 30, 2021 | $2.60M | +127.6% |
| Q2 FY2021 | Jun 30, 2021 | $2.11M | +159.7% |
| Q1 FY2021 | Mar 31, 2021 | $1.56M | +91.1% |
| Q4 FY2020 | Dec 31, 2020 | $1.91M | +149.7% |
| Q3 FY2020 | Sep 30, 2020 | $1.14M | +50.0% |
| Q2 FY2020 | Jun 30, 2020 | $812.00K | +16.4% |
| Q1 FY2020 | Mar 31, 2020 | $818.00K | +39.9% |
| Q4 FY2019 | Dec 31, 2019 | $765.78K | +59.1% |
| Q3 FY2019 | Sep 30, 2019 | $761.88K | +23.4% |
| Q2 FY2019 | Jun 30, 2019 | $697.80K | +4.9% |
| Q1 FY2019 | Mar 31, 2019 | $584.54K | +7.0% |
| Q4 FY2018 | Dec 31, 2018 | $481.29K | -17.3% |
| Q3 FY2018 | Sep 30, 2018 | $617.24K | +4.7% |
| Q2 FY2018 | Jun 30, 2018 | $665.31K | -38.6% |
| Q1 FY2018 | Mar 31, 2018 | $546.33K | -2.0% |
| Q4 FY2017 | Dec 31, 2017 | $582.12K | +9.9% |
| Q3 FY2017 | Sep 30, 2017 | $589.72K | – |
| Q2 FY2017 | Jun 30, 2017 | $1.08M | – |
| Q1 FY2017 | Mar 31, 2017 | $557.70K | – |
| Q4 FY2016 | Dec 31, 2016 | $529.71K | – |
See a number that looks wrong?